Prolife at CPHI Milan 2026: Clinically Validated Cardiovascular Monitoring for International Distribution
CPHI Milan is one of the world's leading pharmaceutical industry events, bringing together manufacturers, distributors, healthcare companies and technology providers to explore new partnerships and commercially ready healthcare innovations. For Prolife, the exhibition provides an opportunity to demonstrate clinically validated cardiovascular monitoring technologies developed for international distribution and long-term market growth.
At the centre of the Prolife showcase — Prolife PX7 Premium and two technologies that bring blood pressure measurement and atrial fibrillation screening into one intelligent measurement process.
Blood Pressure and Atrial Fibrillation — Two Leading Risk Factors for Stroke
Regular home monitoring identifies elevated blood pressure and pulse patterns for further clinical assessment.
Prolife PX7 Premium combines clinically validated blood pressure measurement and atrial fibrillation screening within a single intelligent measurement process, providing healthcare professionals and distribution partners with a differentiated cardiovascular monitoring solution for home use.
Prolife PX7 Premium — One Intelligent Measurement Process
PX7 Premium brings together two of Prolife’s key technologies:
🔸 AFibra™ SMART is Prolife's proprietary atrial fibrillation screening technology developed for home blood pressure monitoring. It supports early identification of pulse irregularities that may require further clinical assessment while remaining fully aligned with recognised medical screening principles.
🔸 AIm technology — AI-adaptive measurement. The measurement process adapts to the individual — to their body, their physiology and their condition. The result is accuracy and comfort that feel personal, whoever is measuring and whenever they measure.Artificial Intelligence Measurement (AIm)
The result is an intelligent process that combines blood pressure measurement and AF screening in one device. AFibra™ SMART serves as a screening aid and does not replace an ECG or diagnosis by a healthcare professional.
The blood pressure measurement accuracy of PX7 Premium has been clinically validated according to the AAMI/ESH/ISO Universal Standard ISO 81060-2:2018, including AMD1:2020 and AMD2:2024. The device is listed by STRIDE BP as a Preferred Device and features a validated cuff range of 22–45 cm.
This approach reflects the Prolife philosophy: health demands control before risks become threats.
For Pharmaceutical and Distribution Partners: Technology Ready for Global Markets
CPHI Milan connects the global pharmaceutical community across development, manufacturing, technology and market access.
For pharmaceutical companies, healthcare organisations and distribution partners, Prolife offers a clinically validated cardiovascular monitoring platform designed for structured market entry, professional recommendation pathways and long-term portfolio development. Clinical validation, intelligent technologies and recognised international standards create a solution with clear market differentiation, grounded in clinical validation and recognised international standards.
Each Prolife solution is supported by clinical validation, regulatory compliance and technologies developed for international healthcare markets, helping partners introduce cardiovascular monitoring solutions with greater commercial confidence and market readiness.
At CPHI Milan 2026, the Prolife team will meet current and prospective partners to discuss international distribution, structured market entry, portfolio expansion and opportunities to develop long-term partnerships in cardiovascular monitoring.
To schedule a meeting in advance, please contact us.
Meet Prolife at CPHI Milan 2026
📍 6–8 October 2026
📍 Fiera Milano, Italy
📍Booth 6J22
Meet Prolife in Milan and experience clinically validated cardiovascular monitoring, ready for global markets.